公开(公告)号：US5807734A

公开(公告)日：1998-09-15

申请号：US456221

申请日：1995-05-31

申请人： Michael L. Diegel ,  Peter S. Linsley ,  Lisa K. Gilliland ,  Patricia A. Moran ,  Joyce M. Zarling ,  Jeffrey A. Ledbetter

发明人： Michael L. Diegel ,  Peter S. Linsley ,  Lisa K. Gilliland ,  Patricia A. Moran ,  Joyce M. Zarling ,  Jeffrey A. Ledbetter

IPC分类号： C12N15/09 ,  A61K38/00 ,  A61K39/395 ,  A61K47/48 ,  A61P31/12 ,  A61P31/18 ,  C07K16/00 ,  C07K16/28 ,  C12N1/21 ,  C12N15/00 ,  C12N15/13 ,  C12P21/08 ,  C12R1/19 ,  C07H21/04 ,  C12N1/20 ,  C12N15/11

CPC分类号： C07K16/2806 ,  A61K47/48561 ,  C07K16/00 ,  A61K38/00 ,  C07K2317/73 ,  C07K2319/30

摘要： An anti-CD2 monoclonal antibody according to the present invention can be: (1) a chimeric monoclonal antibody CD2 SFv-Ig produced by expression of the construct cloned in recombinant Escherichia coli culture ATCC No. 69277; (2) a monoclonal antibody having complementarity-determining regions identical with those of CD2 SFv-Ig; or (3) a monoclonal antibody competing with CD2 SFv-Ig for binding to CD2 antigen at least about 80% as effectively on a molar basis as CD2 SFv-Ig. Anti-CD2 monoclonal antibodies according to the present invention, as well as other antibodies that can modulate the interactions between T lymphocytes and monocytes, can be used to inhibit the production of HIV-1 by HIV-1-infected T cells in HIV-1-infected patients. In another use, T cells treated in vitro can be reinfused into AIDS patients to increase the proportion of functional, non-HIV-1-producing T cells in the patient.

摘要翻译： 根据本发明的抗CD2单克隆抗体可以是：（1）通过表达克隆在重组大肠杆菌培养物ATCC No.69277中的构建体产生的嵌合单克隆抗体CD2 SFv-Ig; （2）具有与CD2 SFv-Ig相同的互补决定区的单克隆抗体; 或（3）与CD2 SFv-Ig竞争结合CD2抗原的单克隆抗体与CD2 SFv-Ig按摩尔计有效地至少约80％。 根据本发明的抗CD2单克隆抗体以及可以调节T淋巴细胞和单核细胞之间的相互作用的其它抗体可用于抑制HIV-1感染的HIV-1感染的T细胞在HIV-1中的产生 感染患者。 在另一种用途中，体外治疗的T细胞可以再次输入艾滋病患者，以增加患者功能性，非HIV-1产生的T细胞的比例。

公开(公告)号：US5795572A

公开(公告)日：1998-08-18

申请号：US68946

申请日：1993-05-25

申请人： Michael L. Diegel ,  Peter S. Linsley ,  Lisa K. Gilliland ,  Patricia A. Moran ,  Joyce M. Zarling ,  Jeffrey A. Ledbetter

发明人： Michael L. Diegel ,  Peter S. Linsley ,  Lisa K. Gilliland ,  Patricia A. Moran ,  Joyce M. Zarling ,  Jeffrey A. Ledbetter

IPC分类号： C12N15/09 ,  A61K38/00 ,  A61K39/395 ,  A61K47/48 ,  A61P31/12 ,  A61P31/18 ,  C07K16/00 ,  C07K16/28 ,  C12N1/21 ,  C12N15/00 ,  C12N15/13 ,  C12P21/08 ,  C12R1/19 ,  A61K39/44 ,  G01N33/53

CPC分类号： C07K16/2806 ,  A61K47/48561 ,  C07K16/00 ,  A61K38/00 ,  C07K2317/73 ,  C07K2319/30

摘要： An anti-CD2 monoclonal antibody according to the present invention can be: (1) a chimeric monoclonal antibody CD2 SFv-Ig produced by expression of the construct cloned in recombinant Escherichia coli culture ATCC No. 69277; (2) a monoclonal antibody having complementarity-determining regions identical with those of CD2 SFv-Ig; or (3) a monoclonal antibody competing with CD2 SFv-Ig for binding to CD2 antigen at least about 80% as effectively on a molar basis as CD2 SFv-Ig. Anti-CD2 monoclonal antibodies according to the present invention, as well as other antibodies that can modulate the interactions between T lymphocytes and monocytes, can be used to inhibit the production of HIV-1 by HIV-1-infected T cells in HIV-1-infected patients. In another use, T cells treated in vitro can be reinfused into AIDS patients to increase the proportion of functional, non-HIV-1-producing T cells in the patient.